Teva Pharmaceutical Industries Limited (NYSE:TEVA) finished Thursday with an addition of $0.16 to close at $9.34, an upside of 1.74 percent. An average of 6,859,860 shares of common stock have been traded in the last five days. There was a gain of $0.47 in the past week, and it reached a new high 16 times over the past 12 months. The last 20 days have seen an average of 8,787,560 shares traded, while the 50-day average volume stands at 9,104,994.
TEVA stock has increased by 7.73% in the last month. The company shares reached their 1-month lowest point of $8.24 on 12/08/22. With the stock rallying to its 52-week high on 08/11/22, shares of the company touched a low of $6.78 and a high of $11.34 in 52 weeks. It has reached a new high 19 times so far this year and achieved 16.60% or $1.33 in price. In spite of this, the price is down -17.64% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
TEVA stock investors should be aware that Teva Pharmaceutical Industries Limited (TEVA) stock had its last reported insider trading activity 130 days ago on Aug 22. In this transaction, the insider spent $558,696. Exec. VP Chief Legal Officer, Stark David Matthew, disposed of 58,163 shares at a price of $9.04 on Jul 28. The insider now owns more than $525,590 worth of shares. Prior to that, Executive VP, Global R&D Fridriksdottir Hafrun went on to Sale 130,000 shares at $8.22 each on May 17. An amount of $1,068,067 was transacted.
Teva Pharmaceutical Industries Limited (TEVA) stock’s beta is 1.19. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.70, the price-to-book (PB) ratio at 1.18, and the price-to-cash flow ratio at 20.54.
The quick ratio of Teva Pharmaceutical Industries Limited for the three months ended June 29 was 0.70, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.11 and a total debt to equity ratio of 2.43 for the quarter ending June 29. Teva Pharmaceutical Industries Limited’s EBITDA margin for the year ending June 29 is 27.75%, while its operating margin for the same period stands at -7.70%. Its gross profit as reported stood at $7.59 billion compared to revenue of $15.88 billion.
For the three-month period that ended June 29, Teva Pharmaceutical Industries Limited had $18.5 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $56.0 million in the quarter, while revenues were shrunk -421.43%. The analyst consensus anticipated Teva Pharmaceutical Industries Limited’s latest quarter earnings to come in at $0.56 per share, but it turned out to be $0.68, a 21.40% surprise. For the quarter, EBITDA amounted to $764.0 million. Shareholders own equity worth $1.11 billion.
From a technical analysis perspective, let’s take a brief look at Teva Pharmaceutical Industries Limited (TEVA) price momentum. RSI 9-day as of the close on 29 December was 65.82%, suggesting the stock is Neutral, with historical volatility in this time frame at 41.06%.
As of today, TEVA’s price is $9.23 +5.30% or $0.47 from its 5-day moving average. TEVA is currently trading +6.50% higher than its 20-day SMA and -15.32% lower than its 100-day SMA. However, the stock’s current price level is +12.39% above the SMA50 and +24.53% above the SMA200.
The stochastic %K and %D were 85.21% and 84.01%, respectively, and the average true range (ATR) was 0.29. With the 14-day stochastic at 93.09% and the average true range at 0.30, the RSI (14) stands at 61.14%. The stock has reached 0.25 on the 9-day MACD Oscillator while the 14-day reading was at 0.29.
JP Morgan downgraded Teva Pharmaceutical Industries Limited (NYSE: TEVA) to a an Underweight rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Teva Pharmaceutical Industries Limited (TEVA) among analysts is Hold. According to current brokerage recommendations, 3 brokerage firms advise that investors sell TEVA, while 6 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 3 others rate it as a “buy”.
What is TEVA’s price target for the next 12 months?
Analysts predict a range of price targets between $7.00 and $13.00, with a median target of $10.00. Taking a look at these predictions, the average price target given by analysts for Teva Pharmaceutical Industries Limited (TEVA) stock is $9.67.